K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.

K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.

Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapies exist targeting this oncogene. K-RAS signals via downstream effector pathways such as the MAPK and the PI3K signaling pathways, and much effort has been focused on developing drugs targeting compone...

Full description

Bibliographic Details
Main Authors: Irmgard Hofmann, Andreas Weiss, Gaelle Elain, Maria Schwaederle, Dario Sterker, Vincent Romanet, Tobias Schmelzle, Albert Lai, Saskia M Brachmann, Mohamed Bentires-Alj, Thomas M Roberts, William R Sellers, Francesco Hofmann, Sauveur-Michel Maira
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3432074?pdf=render

Internet

http://europepmc.org/articles/PMC3432074?pdf=render

Similar Items